'What fatigue?' Auckland Health offers view of GTG settlement
12 July, 2005 by Graeme O'NeillThe Auckland District Health Board has offered its own perspective on the out-of-court settlement of its dispute with Victorian biotech Genetic Technologies (ASX:GTG) over GTG's request for AUD$12 million in licensing and royalty payments for NZ agencies using its proprietary gene-testing and gene-mapping technologies.
Neuren extends US partnership
11 July, 2005 by Graeme O'NeillPreclinical trials of Auckland biopharma Neuren's (ASX:NEU latest neuroprotectant, NNZ-2566, have convinced the US Army's Walter Reed Research Institute in Washington to back a clinical trial of the new drug in brain-trauma patients.
Hughes grants flow to local malaria researchers
11 July, 2005 by Graeme O'NeillThe latest list of international research grants from the Howard Hughes Medical Institute (HHMI) has confirmed Australia's status as a leading nation in malaria research.
Meditech signs collaboration agreement with US firm Hyalose
08 July, 2005 by Helen SchullerCancer therapy developer Meditech (ASX:MTR) has signed a research and development collaboration agreement with Hyalose, a privately-owned US biotech company.
WEHI to share in US$21 million Gates grant for malaria research
07 July, 2005 by Ruth BeranProf Alan Cowman and his team at The Walter and Eliza Hall Institute of Medical Research (WEHI) are part of an international consortium that has won a US$13 million Grand Challenge in Global Health grant to develop a treatment for malaria.
Life Therapeutics sets out to acquire US firm Pyramid Biological
04 July, 2005 by Ruth BeranSydney-based Life Therapeutics (ASX:LFE) has firmed up its stake in the global plasma supply industry, issuing a definitive letter of intent to acquire privately-held California-based Pyramid Biological for US$13 million, plus assumption of US$7 million debt.
In brief: Acrux, Psiron, Circadian
29 June, 2005 by Ruth BeranAcrux (ASX:ACR) has received a US$1 million milestone payment from Vivus for its estradiol transdermal spray product Evamist, currently in Phase III clinical trials to treat menopausal symptoms in the US, which was due today.
Gates Foundation funds UQ dengue research
28 June, 2005 by Graeme O'NeillUniversity of Queensland parasitologist Prof Scott O'Neill has won a prestigious grant from the Bill and Melinda Gates Foundation in the US to work on a remarkable symbiotic bacteria that induces sterility in insects.
Brain pacemaker could ease severe depression - study
28 June, 2005 by Staff WritersPatients suffering from severe depression who have not responded to other treatments may be helped by deep brain stimulation, researchers said.
Chemgenex and Stragen Pharma to create alliance
28 June, 2005 by Ruth BeranMelbourne- and Californian-based ChemGenex Pharmaceuticals (ASX:CXS) has formed an international alliance with Geneva-based Stragen Pharma to accelerate the clinical development of ChemGenex's lead anti-cancer therapeutic, Ceflatonin.
New melanoma research centre for Perth
24 June, 2005 by Susan WilliamsonResearch in to the genetic causes of melanoma will be the focus of the new Scott Kirkbride Melanoma Research Centre, recently established at the University of Western Australia's Centre for Medical Research in Perth.
Funding for bioactive polymers in wound healing
23 June, 2005 by Susan WilliamsonThe development of nano-sized microcapsules and bioactive bandages to assist in the delivery of the synthetic growth factor complex, VitroGro, is one of 251 projects to be funded in the latest round of the Australian Research Council's (ARC) Linkage Projects scheme.
In Brief: Psivida, Compumedics, Avantogen
22 June, 2005 by Ruth BeranPsivida (ASX:PSD) has released the full results of its Phase IIa trial of BrachySil in inoperable primary liver cancer patients, showing that the product is safe and effective in prompting tumour regression.
State governments fund research initiatives
22 June, 2005 by Susan WilliamsonSpeaking at BIO 2005 in Philadelphia, Victorian premier Steve Bracks announced a new AUD$63 million initiative to fund the new Victorian Neurotrauma Initiative (VNI).
Biosceptre diagnostic detects ovarian cancer
22 June, 2005 by Ruth BeranA study by Peptech's (ASX:PTD) joint venture partner Biosceptre has found that its diagnostic test successfully identified ovarian cancer in tissue analysis, paving the way for the development of a commercial test for this disease.
